Biocon Biologics Limited (BBL), a subsidiary of Biocon, on Thursday announced a strategic alliance with Serum Institute Life Sciences (SILS). As per the agreement, BBL will offer approximately 15% stake to SILS for access to a 100 million doses of vaccines per annum for 15 years.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
